Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus NORLESTRIN 28 1 50.
ENSKYCE vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive